AstraZeneca Results Presentation Deck
Oncology: R&D pipeline highlights
Strong congress presence; HIMALAYA and TOPAZ-1 support launch into GI cancers
• TROPION-PanTumor01: promising
●
evidence of the anti-tumour activity of
datopotamab deruxtecan in TNBC¹
Antitumor Responses by BICR
Patients with TNBC without prior Topo I inhibitor-based ADC
Best Percent Change in SoD From Baseline
by BICR (n=26)
100
80-
60-
40
-20
-40
SABCS
Enhertu, Dato-DXd, Lynparza,
Imfinzi and camizestrant
-60 -
-80
-100
Dose level
8 mg/kg
6 mg/kg
Patients, n (%)³
ORR
CR/PR (confirmed)
CR/PR (pending confirmation)
Non-CR/non-PD
Stable disease
Not evaluable
Disease control rate
PD
SG/DXd Naïve Patients with
Measurable Disease at BL
(n=27)
14 (52)
13 (48)
1 (4)
0
9 (33)
1 (4)
22 (81)
4 (15)
Median follow-up: 8.8 months (range, 4-13 months)
• ASCEND: durable efficacy for
Calquence over three years in r/r
CLL²
Progression-Free Survival (%)
100++
80-
60-
40-
20-
0-
ASH
Calquence
and capivasertib
Acalabrutinib vs IdR vs BR
Acalabrutinib:ldR
HR (95% CI): 0.31 (0.22, 0.43)
P<0.0001⁰
Acalabrutinib:BR
HR (95% CI): 0.25 (0.16, 0.40)
P<0.0001
Acalabrutinib
IdR
BR
9 10 11 12 13 14 15 16 17 18 19 20 21
Months
Median PFS: NR
63%
Median PFS: 16.2 mo
Median PFS: 18.6 mo
33 34 35 36 37 38 39 40 41 42
No. at risk
Acalabrutinib 155 154 153 151 148 147 143 142 142 139 138 137 133 131 129 128 127 12
IR 110116116114113112106 00 00 00 82 81 73 72 66 57 56 52 40 40 40 48 45 41 40 37 35 35 32 32 29 28 27 27
BR 36 34 34 33 33 33 32 30 29 28 27 26 22 22 20 19 18 17 17 16 14 14 13 12 12 10 8 8 7 7 6 6 5 5 4 3 2 2 1
0
• Positive results in IO: HIMALAYA (HCC)
and TOPAZ-1 (BTC)
Enhertu gastric and colorectal trials³
●
DESTINY-CRC01
Best Percentage Change in Tumor Size in Cohort A
Best Percentage Change From Baseline in the Sum
of Diameters of Measurable Tumors
20
-40
-60
ASCO GI
Imfinzi, tremelimumab
and Enhertu
-80
-100
HER2 IHC 3+ or IHC 2+/ISH+ Cohort A (n = 49³)
IHC 3+
IHC 2+/ISH+
Prior anti-HER2 treatment
HER2 IHC 2+/ISH+ with an NRAS mutation
Wealth of new data reinforces leadership in Oncology, underscoring ambition to redefine cancer care
20 SABCS = San Antonio Breast Cancer Symposium; TNBC = triple negative breast cancer; ASH = American Society of Hematology; ASCO GI American Society of Clinical Oncology Gastrointestinal Cancers Symposium 1. Krop et al, SABCS
2021, Presentation number GS1-05. 2. Jurczak et al, ASH 2021 Presentation abstract number 393. 3. Yamaguchi et al, ASCO GI Presentation abstract number 242.View entire presentation